The life and legacy of Dr. C. Wayne Bardin, former director of the Population Council’s Center for Biomedical Research (CBR) and chairman of the International Committee for Contraception Research at the Population Council, was honored at the New York Times. James Sailer, CBR’s current Executive Director, spoke about Dr. Bardin’s groundbreaking work.
Dr. Bardin, a pioneer in the field of endocrinology, oversaw research and development of contraceptive technologies like Norplant and Jadelle, and helped oversee the approval process for RU-486. He was a champion of Nestorone, a potent progestin that now serves as the basis of Annovera and the Council's male contraceptive gel that is currently in clinical trial.
Dr. Bardin resolved to invest in new “bench to bedside” research — where the results of laboratory work are used directly on patients — to develop better contraceptive drugs and delivery systems.
“As much as he respected basic research, Dr. Bardin really wanted to see products that would change people’s lives come to fruition,” said James Sailer, the current executive director of the Center for Biomedical Research, in New York City.
Read more about Dr. Bardin’s legacy and CBR at The New York Times.